Scientists classified 315 newly diagnosed AML patients at their center based on the expression of CD11b and CD64. The CD11b+CD64+ populations were identified as independent risk factors for overall survival and event-free survival of AML, exhibiting specific clinicopathological features.
[Cellular Oncology]